CLINUVEL Reports December Half Year Operating Results
Filed with ASX · · 4 pages · English
CLINUVEL PHARMACEUTICALS LTD today announced a record December half year operating profit with the release of its Half Yearly Report for the six months ending 31 December 2021. KEY HIGHLIGHTS, HALF YEAR ENDED 31 DECEMBER 2021 Change from Consolidated Entity Result same period 2020 Total Revenues $24,631,000 +56% Total Expenses $16,230,000 +67% Net Profit before income tax $8,726,000 +50% Cash and
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- Appendix 4D Half Year Report
- Response to ASX Price Query
- CLINUVEL Delivers Record Revenues and Profit
- Appendix 4E and Preliminary Financial Report
- Appendix 4C - quarterly
Later from Clinuvel Pharmaceuticals
- afamelanotide in Stroke (AIS) - Positive Preliminary Results
- ACTH Manufacturing Update
- Positive Final Results in Stroke Study CUV801
- Appendix 4E and Annual Report 2022
- S&P DJI Announces September 2022 Quarterly Rebalance
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals